1352035-47-2

Upstream product

• 5122-95-2 3-Biphenylboronic acid 
• 1352036-19-1 3-([1,1'-biphenyl]-3-yl)-6,7-dimethoxyisoquinolin-1(2H)-one 
• 1352036-16-8 3-bromo-6,7-dimethoxyisoquinolin-1-one 
• 24634-09-1 2-(cyanomethyl)-4,5-dimethoxybenzoyl chloride 
• 2107-85-9 5,6-dimethoxy-indan-1,2-dione-2-oxime 
• 76254-26-7 2-(cyanomethyl)-4,5-dimethoxybenzoic acid 
• 2107-69-9 5,6-dimethoxy-1-indanone 
• 1352036-20-4 3-([1,1'-biphenyl]-3-yl)-1-chloro-6,7-dimethoxyisoquinoline 

Relevant academic research and scientific papers

3-Phenyl substituted 6,7-dimethoxyisoquinoline derivatives as FtsZ-targeting antibacterial agents

The emergence of multidrug-resistant bacteria has created an urgent need for antibiotics with a novel mechanism of action. The bacterial cell division protein FtsZ is an attractive target for the development of novel antibiotics. The benzo[c]phenanthridinium sanguinarine and the dibenzo[a,g]quinolizin-7-ium berberine are two structurally similar plant alkaloids that alter FtsZ function. The presence of a hydrophobic functionality at either the 1-position of 5-methylbenzo[c]phenanthridinium derivatives or the 2-position of dibenzo[a,g]quinolizin-7-ium derivatives is associated with significantly enhanced antibacterial activity. 3-Phenylisoquinoline represents a subunit within the ring-systems of both of these alkaloids. Several 3- phenylisoquinolines and 3-phenylisoquinolinium derivatives have been synthesized and evaluated for antibacterial activity against Staphylococcus aureus and Enterococcus faecalis, including multidrug-resistant strains of methicillin-resistant S. aureus (MRSA) and vancomycin-resistant E. faecalis (VRE). A number of derivatives were found to have activity against both MRSA and VRE. The binding of select compounds to S. aureus FtsZ (SaFtsZ) was demonstrated and characterized using fluorescence spectroscopy. In addition, the compounds were shown to act as stabilizers of SaFtsZ polymers and concomitant inhibitors of SaFtsZ GTPase activity. Toxicological assessment of select compounds revealed minimal cross-reaction mammalian β-tubulin as well as little or no human cytotoxicity.

ANTIMICROBIAL AGENTS

The invention provides a compound of formula (I): or a salt or prodrug thereof, wherein R1, R4-R8, R10, R2'-R6', W, and A have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as antibacterial agents.